Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a single ablative fractional laser treatment significantly reduced hedgehog pathway gene expression in microscopic murine basal cell carcinomas, nearly matching the effects of repeated topical vismodegib applications.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

In this study, plerixafor was found to enhance melanogenesis and promote repigmentation by engaging a β-arrestin–β-catenin–MITF signaling axis in melanocytes, and showed effectiveness in restoring depigmentation in a murine model without causing systemic toxicity.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

In a randomized phase 2b clinical trial, oral ritlecitinib significantly reduced facial vitiligo area scores in patients with active nonsegmental vitiligo compared to placebo, with a favorable safety profile observed over 48 weeks, suggesting its potential as an effective treatment option (Ezzedine et al., 2023).

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study reports a rare side effect of trichiasis in a patient with spinal chordoma treated with Afatinib, a type of epidermal growth factor receptor tyrosine kinase inhibitor.

Sorafenib can cause a temporary skin condition that goes away after stopping the drug.

In this study, researchers examined Baricitinib's role as a treatment for Alopecia Areata, contrasting it with conventional therapies, and found that while effective, Baricitinib may cause adverse reactions depending on individual patient health histories.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

In this case report, researchers observed hair repigmentation in a man with metastatic renal cell carcinoma during treatment with axitinib, marking the first documented instance of this effect with axitinib without the use of hair dyes or other medications.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

This case report highlights a 33-year-old female with systemic lupus erythematosus and refractory alopecia who experienced significant hair regrowth after treatment with tofacitinib, maintained even after glucocorticoid tapering over two years.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

In this study, researchers reviewed cases of EGFR inhibitor-induced folliculitis decalvans and reported the first known occurrences associated with afatinib in three female NSCLC patients, highlighting the importance of early diagnosis and management to improve patient quality of life.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.